Literature DB >> 20883710

Functional and inflammatory alterations in the lung following exposure of rats to nitrogen mustard.

Vasanthi R Sunil1, Kinal J Patel, Jianliang Shen, David Reimer, Andrew J Gow, Jeffrey D Laskin, Debra L Laskin.   

Abstract

Nitrogen mustard is a vesicant that causes damage to the respiratory tract. In these studies, we characterized the acute effects of nitrogen mustard on lung structure, inflammatory mediator expression, and pulmonary function, with the goal of identifying mediators potentially involved in toxicity. Treatment of rats (male Wistar, 200-225 g) with nitrogen mustard (mechlorethamine hydrochloride, i.t., 0.25mg/kg) resulted in marked histological changes in the respiratory tract, including necrotizing bronchiolitis, thickening of alveolar septa, and inflammation which was evident within 24h. This was associated with increases in bronchoalveolar lavage protein and cells, confirming injury to alveolar epithelial regions of the lung. Nitrogen mustard administration also resulted in increased expression of inducible nitric oxide synthase and cyclooxygenase-2, pro-inflammatory proteins implicated in lung injury, in alveolar macrophages and alveolar and bronchial epithelial cells. Expression of connective tissue growth factor and matrix metalloproteinase-9, mediators regulating extracellular matrix turnover was also increased, suggesting that pathways leading to chronic lung disease are initiated early in the pathogenic process. Following nitrogen mustard exposure, alterations in lung mechanics and function were also observed. These included decreases in baseline static compliance, end-tidal volume and airway resistance, and a pronounced loss of methacholine responsiveness in resistance, tissue damping and elastance. Taken together, these data demonstrate that nitrogen mustard induces rapid structural and inflammatory changes in the lung which are associated with altered lung functioning. Understanding the nature of the injury induced by nitrogen mustard and related analogs may aid in the development of efficacious therapies for treatment of pulmonary injury resulting from exposure to vesicants.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20883710      PMCID: PMC3954122          DOI: 10.1016/j.taap.2010.09.016

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  38 in total

Review 1.  Functional plasticity of macrophages: reversible adaptation to changing microenvironments.

Authors:  Robert D Stout; Jill Suttles
Journal:  J Leukoc Biol       Date:  2004-06-24       Impact factor: 4.962

2.  Protective effect of various antioxidants on the toxicity of sulphur mustard administered to mice by inhalation or percutaneous routes.

Authors:  O Kumar; K Sugendran; R Vijayaraghavan
Journal:  Chem Biol Interact       Date:  2001-03-14       Impact factor: 5.192

3.  Airway epithelial damage and release of inflammatory mediators in human lung parenchyma after sulfur mustard exposure.

Authors:  J H Calvet; J P Gascard; S Delamanche; C Brink
Journal:  Hum Exp Toxicol       Date:  1999-02       Impact factor: 2.903

4.  Airway and tissue behavior during induced constriction in rats: intravenous vs. aerosol administration.

Authors:  T Nagase; A Moretto; M S Ludwig
Journal:  J Appl Physiol (1985)       Date:  1994-02

5.  Acute and chronic respiratory effects of sulfur mustard intoxication in guinea pig.

Authors:  J H Calvet; P H Jarreau; M Levame; M P D'Ortho; H Lorino; A Harf; I Macquin-Mavier
Journal:  J Appl Physiol (1985)       Date:  1994-02

6.  Reduced sulfur mustard-induced skin toxicity in cyclooxygenase-2 knockout and celecoxib-treated mice.

Authors:  Uri Wormser; Robert Langenbach; Shyamal Peddada; Amnon Sintov; Berta Brodsky; Abraham Nyska
Journal:  Toxicol Appl Pharmacol       Date:  2004-10-01       Impact factor: 4.219

7.  Asthmalike symptoms following intratracheal exposure of Guinea pigs to sulfur mustard aerosol: therapeutic efficacy of exogenous lung surfactant curosurf and salbutamol.

Authors:  Herman P M van Helden; Willem C Kuijpers; Robert V Diemel
Journal:  Inhal Toxicol       Date:  2004-07       Impact factor: 2.724

8.  Chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for Hodgkin disease: fourteen-year follow-up results.

Authors:  K E Dusenbery; B A Peterson; C D Bloomfield
Journal:  Am J Hematol       Date:  1988-08       Impact factor: 10.047

Review 9.  Sulfur mustard: its continuing threat as a chemical warfare agent, the cutaneous lesions induced, progress in understanding its mechanism of action, its long-term health effects, and new developments for protection and therapy.

Authors:  K J Smith; C G Hurst; R B Moeller; H G Skelton; F R Sidell
Journal:  J Am Acad Dermatol       Date:  1995-05       Impact factor: 11.527

10.  Protection from half-mustard-gas-induced acute lung injury in the rat.

Authors:  Shannon D McClintock; Gerd O Till; Milton G Smith; Peter A Ward
Journal:  J Appl Toxicol       Date:  2002 Jul-Aug       Impact factor: 3.446

View more
  24 in total

1.  Role of TNFR1 in lung injury and altered lung function induced by the model sulfur mustard vesicant, 2-chloroethyl ethyl sulfide.

Authors:  Vasanthi R Sunil; Kinal Patel-Vayas; Jianliang Shen; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2010-11-09       Impact factor: 4.219

2.  Characterization of Distinct Macrophage Subpopulations during Nitrogen Mustard-Induced Lung Injury and Fibrosis.

Authors:  Alessandro Venosa; Rama Malaviya; Hyejeong Choi; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Am J Respir Cell Mol Biol       Date:  2016-03       Impact factor: 6.914

Review 3.  Macrophages and inflammatory mediators in pulmonary injury induced by mustard vesicants.

Authors:  Rama Malaviya; Vasanthi R Sunil; Alessandro Venosa; Kinal N Vayas; Rita Businaro; Diane E Heck; Jeffrey D Laskin; Debra L Laskin
Journal:  Ann N Y Acad Sci       Date:  2016-06-28       Impact factor: 5.691

4.  Regulation of Macrophage Foam Cell Formation During Nitrogen Mustard (NM)-Induced Pulmonary Fibrosis by Lung Lipids.

Authors:  Alessandro Venosa; Ley Cody Smith; Alexa Murray; Tanvi Banota; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Sci       Date:  2019-12-01       Impact factor: 4.849

5.  Regulation of Nitrogen Mustard-Induced Lung Macrophage Activation by Valproic Acid, a Histone Deacetylase Inhibitor.

Authors:  Alessandro Venosa; James G Gow; LeRoy Hall; Rama Malaviya; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Sci       Date:  2017-05-01       Impact factor: 4.849

6.  Role of reactive nitrogen species generated via inducible nitric oxide synthase in vesicant-induced lung injury, inflammation and altered lung functioning.

Authors:  Vasanthi R Sunil; Jianliang Shen; Kinal Patel-Vayas; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2012-03-14       Impact factor: 4.219

7.  Protective role of spleen-derived macrophages in lung inflammation, injury, and fibrosis induced by nitrogen mustard.

Authors:  Alessandro Venosa; Rama Malaviya; Andrew J Gow; Leroy Hall; Jeffrey D Laskin; Debra L Laskin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-16       Impact factor: 5.464

Review 8.  Inflammatory mechanisms of pulmonary injury induced by mustards.

Authors:  Rama Malaviya; Vasanthi R Sunil; Alessandro Venosa; Kinal N Vayas; Diane E Heck; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Lett       Date:  2015-10-23       Impact factor: 4.372

9.  Protective Role of Surfactant Protein-D Against Lung Injury and Oxidative Stress Induced by Nitrogen Mustard.

Authors:  Vasanthi R Sunil; Kinal N Vayas; Jessica A Cervelli; Elena V Ebramova; Andrew J Gow; Michael Goedken; Rama Malaviya; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Sci       Date:  2018-11-01       Impact factor: 4.849

10.  Attenuation of acute nitrogen mustard-induced lung injury, inflammation and fibrogenesis by a nitric oxide synthase inhibitor.

Authors:  Rama Malaviya; Alessandro Venosa; Leroy Hall; Andrew J Gow; Patrick J Sinko; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2012-09-06       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.